Role of TRIF-Dependent TLR Signaling in Intestinal Mucosa

TRIF 依赖性 TLR 信号转导在肠粘膜中的作用

基本信息

  • 批准号:
    10225616
  • 负责人:
  • 金额:
    $ 43.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Extensive studies have shown that an aggressive mucosal T cell subset that reacts to intestinal bacteria plays an important role in the cause of inflammatory bowel disease (IBD). These aggressive T cells are thought to live long as immune-memory cells in peripheral blood and contribute to the chronicity and the relapse of the disease. Evidence further suggests that a type of T cells, which flexibly secretes different effector molecules, contributes to the complex pathogenesis of IBD. Another T cell subset, T follicular helper (Tfh)-like cells, causes severe colitis in animal models, and is abundantly found in peripheral blood of IBD patients. Because Tfh-like cells are immune-memory cells with highly flexible secretion of effector molecules and are generated in the intestine, they may contribute significantly to chronic inflammation in IBD. However, the role of Tfh-like cells in intestinal inflammation and the regulatory mechanisms of their function in the intestine have yet to be explored. The objective of this application is to identify the key pathways regulating Tfh-like cell generation and function in the intestine. We have demonstrated that TIR-domain-containing adapter-inducing interferon-β (TRIF), a molecule that is activated by encountering bacteria and viruses, plays an important role in maintaining intestinal homeostasis through direction of T cell activation and function. We have found that TRIF limits the generation of Tfh-like cells and T cell flexibility of effector molecule secretion in the intestine through the pathways induced by four key molecules; IFNAR, IL27, STAT1, and STAT3. Impairment of TRIF amplifies Tfh-like cell generation and plasticity, and increased levels of TRIF results in suppression of Tfh-like number and flexibility. Genetic studies have identified that the abnormalities in the IFNAR, IL27, STAT1, and STAT3 genes are often found in Crohn's disease (CD) patients. Therefore, through the following three aims, we would like to address our hypothesis that impairment of the TRIF-mediated pathways allows increased generation of functionally flexible Tfh-like cells that contribute to chronic inflammation in CD, particularly in patients with genetic variants in the IL27, IFNAR, STAT1, and STAT3 genes. Our specific aims are: (1). Determine the mechanism by which Tfh-like cells perpetuate destructive inflammation in the intestine. (2). Determine the mechanisms by which TRIF regulates pathogenic Tfh-like cell generation. (3). Determine the functional consequence of genetic variants within TRIF-mediated pathways in the generation of pathogenic Tfh-like cells in patients with CD. Understanding target pathways affecting the generation of highly aggressive T cells may suggest novel approaches, such as precision medicine, in the management of the subsets of IBD patients in which inflammation is caused by these T cells. The outcome of this project will be novel insight into the essential regulatory mechanisms of highly aggressive T cell populations, which is expected to have a major impact in our understanding of mucosal immunology, as well as in the future therapy of many chronic inflammatory diseases including IBD.
广泛的研究表明,对肠道细菌作用反应的侵袭性粘膜T细胞子群 在炎症性肠病(IBD)的原因中的重要作用。这些侵略性的T细胞被认为 寿命长时间为外周血中的免疫记忆细胞,并有助于慢性和继电器 疾病。证据进一步表明,一种T细胞(灵活地秘密效应分子)的一种类型的T细胞, 有助于IBD的复杂发病机理。另一个T细胞子集T卵泡辅助器(TFH)样细胞, 在动物模型中引起严重的结肠炎,基本上是在IBD患者的外周血中发现的。因为 TFH样细胞是具有高度柔韧性分子分泌的免疫记忆细胞,并在 肠,它们可能会对IBD的慢性炎症产生重大贡献。但是,TFH样细胞的作用 在肠道炎症及其功能在肠道中的调节机制尚未是 探索。该应用的目的是确定调节TFH样细胞产生的关键途径和 在肠中的功能。我们已经证明了含TIR域的衔接子诱导的干扰素-β (TRIF)是一种通过遇到细菌和病毒激活的分子,在 通过T细胞激活和功能的方向维持肠内稳态。我们发现Trif 通过限制TFH样细胞的产生和T细胞在肠中效应分子分泌的柔韧性 四个关键分子诱导的途径; IFNAR,IL27,STAT1和STAT3。 TRIF扩增的损害 TFH样细胞的产生和可塑性以及TRIF的水平增加导致TFH样数量抑制 和灵活性。遗传研究已经确定IFNAR,IL27,STAT1和STAT3的异常 基因经常在克罗恩病(CD)患者中发现。因此,通过以下三个目标,我们将 想解决我们的假设,即Trif介导的途径的损害使生成增加 在功能上有助于CD的慢性炎症的功能柔性TFH样细胞,特别是在患者中 IL27,IFNAR,STAT1和STAT3基因中的遗传变异。我们的具体目标是:(1)。确定 TFH样细胞在肠道中永久注射的机制。 (2)。确定 TRIF调节致病性TFH样细胞产生的机制。 (3)。确定功能 在致病性TFH样细胞的产生中,TRIF介导的途径内遗传变异的结果 在CD患者中。了解影响高度攻击性T细胞产生的目标途径可能 建议在IBD患者子集管理中采用新颖的方法,例如精密医学 哪些炎症是由这些T细胞引起的。该项目的结果将是对 高度攻击性T细胞种群的基本调节机制,预计将具有主要的调节机制 对我们对粘膜免疫学的理解以及许多慢性的未来治疗的影响 包括IBD在内的炎症性疾病。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
TRIF mobilizes unique primary defense against Gram-negative bacteria in intestinal interface.
TRIF 在肠道界面动员针对革兰氏阴性菌的独特初级防御。
  • DOI:
    10.4161/gmic.20873
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    12.2
  • 作者:
    Sotolongo,John;Kanagavelu,Saravana;Hyun,Jinhee;Ruiz,Jose;Fukata,Masayuki
  • 通讯作者:
    Fukata,Masayuki
Systemic Activation of TLR3-Dependent TRIF Signaling Confers Host Defense against Gram-Negative Bacteria in the Intestine.
TIR Domain-Containing Adapter-Inducing Beta Interferon (TRIF) Mediates Immunological Memory against Bacterial Pathogens.
含有 TIR 结构域的接头诱导 β 干扰素 (TRIF) 介导针对细菌病原体的免疫记忆。
  • DOI:
    10.1128/iai.00674-15
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    Kanagavelu,Saravana;Flores,Claudia;Termini,JM;Romero,Laura;Riveron,Reldy;Ruiz,Jose;Arditi,Moshe;Schesser,Kurt;Fukata,Masayuki
  • 通讯作者:
    Fukata,Masayuki
TIR-domain-containing adapter-inducing interferon-β (TRIF) regulates Th17-mediated intestinal immunopathology in colitis.
  • DOI:
    10.1038/mi.2014.67
  • 发表时间:
    2015-03
  • 期刊:
  • 影响因子:
    8
  • 作者:
  • 通讯作者:
A unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses.
  • DOI:
    10.1016/j.micinf.2012.10.011
  • 发表时间:
    2013-01
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    Hyun J;Kanagavelu S;Fukata M
  • 通讯作者:
    Fukata M
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephan R. Targan其他文献

Serial 6-mercaptopurine (6-MP) metabolite measurements in combination with dose escalation unmasks an important biochemical explanation for "6-MP resistance"
  • DOI:
    10.1016/s0016-5085(00)85698-x
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marla C. Dubinsky;Philip V. Hassard;Lori Y. Kam;Maria T. Abreu;Ernest G. Seidman;Stephan R. Targan;Eric A. Vasiliauskas
  • 通讯作者:
    Eric A. Vasiliauskas
Thioguanine (6-TG): A therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine (6-MP)
  • DOI:
    10.1016/s0016-5085(00)85701-7
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marla C. Dubinsky;Philip V. Hassard;Maria T. Abreu;Lori Y. Kam;Ernest G. Seidman;Stephan R. Targan;Eric A. Vasiliauskas
  • 通讯作者:
    Eric A. Vasiliauskas
Tu1740 – Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 Unifi Maintenance Study
  • DOI:
    10.1016/s0016-5085(19)39726-4
  • 发表时间:
    2019-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Gert A. Van Assche;Stephan R. Targan;Thomas Baker;Christopher D. O'Brien;Hongyan Zhang;Jewel Johanns;Philippe Szapary;Colleen W. Marano;Rupert W. Leong;David Rowbotham;Tadakazu Hisamatsu;Silvio Danese;Bruce E. Sands;Laurent Peyrin-Biroulet
  • 通讯作者:
    Laurent Peyrin-Biroulet
Tu1764 - Tl1A Deficiency (But not Dr3-Deficiency) Protects from the Development of Colitis in the Chronic T Cell Transfer Mouse Model by Decreasing Th1 Cell Accumulation in the Intestinal Mucosa
  • DOI:
    10.1016/s0016-5085(18)33390-0
  • 发表时间:
    2018-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Yosuke Shimodaira;Yoshitake Kanazawa;Jay P. Abraham;Kotaro Kumagai;Noam Jacob;Yuefang Ye;Justin Luu;Kathrin S. Michelsen;Stephan R. Targan;David Shih
  • 通讯作者:
    David Shih
Tu1797 - Multi-Center Cohort Analysis Identified a Genetic Association in Complement Factor B with Perianal Crohn's Disease
  • DOI:
    10.1016/s0016-5085(18)33423-1
  • 发表时间:
    2018-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marcy Akhlaghpour;Talin Haritunians;Emebet Mengesha;Dalin Li;Zhenqiu Liu;Randall McNally;Carol Landers;Karen Zaghiyan;Phillip Fleshner;Gil Melmed;Stephan R. Targan;Mark S. Silverberg;Kathrin S. Michelsen;Dermot McGovern
  • 通讯作者:
    Dermot McGovern

Stephan R. Targan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stephan R. Targan', 18)}}的其他基金

Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD
IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制
  • 批准号:
    10077845
  • 财政年份:
    2020
  • 资助金额:
    $ 43.75万
  • 项目类别:
Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD
IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制
  • 批准号:
    10539302
  • 财政年份:
    2020
  • 资助金额:
    $ 43.75万
  • 项目类别:
Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD
IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制
  • 批准号:
    10311509
  • 财政年份:
    2020
  • 资助金额:
    $ 43.75万
  • 项目类别:
Molecular characterization of the role of RNASET2 in Severe Crohn's Disease
RNASET2 在严重克罗恩病中作用的分子表征
  • 批准号:
    10021036
  • 财政年份:
    2019
  • 资助金额:
    $ 43.75万
  • 项目类别:
Molecular characterization of the role of RNASET2 in Severe Crohn's Disease
RNASET2 在严重克罗恩病中作用的分子表征
  • 批准号:
    10226172
  • 财政年份:
    2019
  • 资助金额:
    $ 43.75万
  • 项目类别:
IBD: Mucosa Specific Regulation of IFN-gamma Production
IBD:粘膜对 IFN-γ 产生的特异性调节
  • 批准号:
    7921223
  • 财政年份:
    2009
  • 资助金额:
    $ 43.75万
  • 项目类别:
INFLAMMATORY BOWEL DISEASE CENTER: CLINICAL DATA REPOSITORY - TISSUE PROCUREMENT
炎症性肠病中心:临床数据存储库 - 组织采购
  • 批准号:
    8174459
  • 财政年份:
    2009
  • 资助金额:
    $ 43.75万
  • 项目类别:
INFLAMMATORY BOWEL DISEASE CENTER: CLINICAL DATA REPOSITORY - TISSUE PROCUREMENT
炎症性肠病中心:临床数据存储库 - 组织采购
  • 批准号:
    7952200
  • 财政年份:
    2008
  • 资助金额:
    $ 43.75万
  • 项目类别:
CORE--TISSUE PROCUREMENT & DATA ANALYSIS & SERUM ANALYSIS
核心——纸巾采购
  • 批准号:
    7487329
  • 财政年份:
    2007
  • 资助金额:
    $ 43.75万
  • 项目类别:
INFLAMMATORY BOWEL DISEASE CENTER: CLINICAL DATA REPOSITORY - TISSUE PROCUREMENT
炎症性肠病中心:临床数据存储库 - 组织采购
  • 批准号:
    7606129
  • 财政年份:
    2007
  • 资助金额:
    $ 43.75万
  • 项目类别:

相似国自然基金

肾—骨应答调控骨骼VDR/RXR对糖尿病肾病动物模型FGF23分泌的影响及中药的干预作用
  • 批准号:
    82074395
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
基于细胞自噬调控的苦参碱对多囊肾小鼠动物模型肾囊肿形成的影响和机制研究
  • 批准号:
  • 批准年份:
    2019
  • 资助金额:
    33 万元
  • 项目类别:
    地区科学基金项目
NRSF表达水平对抑郁模型小鼠行为的影响及其分子机制研究
  • 批准号:
    81801333
  • 批准年份:
    2018
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目
靶向诱导merlin/p53协同性亚细胞穿梭对听神经瘤在体生长的影响
  • 批准号:
    81800898
  • 批准年份:
    2018
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目
伪狂犬病病毒激活三叉神经节细胞对其NF-кB和PI3K/Akt信号转导通路影响的分子机制研究
  • 批准号:
    31860716
  • 批准年份:
    2018
  • 资助金额:
    39.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Endothelial Cell Reprogramming in Familial Intracranial Aneurysm
家族性颅内动脉瘤的内皮细胞重编程
  • 批准号:
    10595404
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Dravet Syndrome Anti-Epileptic Control by Targeting GIRK Channels
通过针对 GIRK 通道进行 Dravet 综合征抗癫痫控制
  • 批准号:
    10638439
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Novel application of pharmaceutical AMD3100 to reduce risk in opioid use disorder: investigations of a causal relationship between CXCR4 expression and addiction vulnerability
药物 AMD3100 降低阿片类药物使用障碍风险的新应用:CXCR4 表达与成瘾脆弱性之间因果关系的研究
  • 批准号:
    10678062
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Mechanisms of Metal Ion Homeostasis of Oral Streptococci
口腔链球菌金属离子稳态机制
  • 批准号:
    10680956
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
Design and testing of a novel circumesophageal cuff for chronic bilateral subdiaphragmatic vagal nerve stimulation (sVNS)
用于慢性双侧膈下迷走神经刺激(sVNS)的新型环食管套囊的设计和测试
  • 批准号:
    10702126
  • 财政年份:
    2023
  • 资助金额:
    $ 43.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了